The US FDA has posted details, including company and FDA Briefing Materials, for the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) meeting on Wednesday, October 19, 2016. The Committee will discuss new drug application (NDA) 201656 for desmopressin, submitted by Serenity Pharmaceuticals, LLC (Serenity) for the proposed treatment of adult onset nocturia. In 2010, Serenity and Allergan, Inc. (Allergan) announced an agreement on its development and commercialization.

See the SAC Tracker report